Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase Ib/II Study of the Microenvironment Modifier L-DOS47 Plus Doxorubicin for the Treatment of Patients With Previously Treated Advanced Pancreatic Cancer

Summary

This phase Ib/II study will evaluate the safety and tolerability of escalating doses of L-DOS47 in combination with doxorubicin, as well as preliminary anti-tumor activity in patients with previously treated advanced pancreatic cancer.

General Information

NCT#: NCT04203641
Study ID: LDOS006
Trial Phase: Phase I/II

Trial Sponsor: Theradex, Helix BioPharma Corporation
Therapies Used in This Trial: Doxorubicin, L-DOS47

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search